|
|
 |
 |
Biopharmaceutical Companies Present
Promising Data for Treating PAH
Three biopharmaceutical companies present data about
products that show great promise for the treatment of
pulmonary arterial hypertension during the annual American
Thoracic Society Meeting.
- Encysive Pharmaceuticals Announces New STRIDE-2
Data Presented at American Thoracic Society International
Conference. Read
story.
- Encysive Pharmaceuticals Submits New Drug Application
for Thelin™. Read
story.
- Ambrisentan PAH Long-term Safety and Efficacy Data
Presented at ATS 2005 – San Diego. Read
story.
- Researchers Present Data That Support Inhaled Iloprost
Therapy in Patients With Pulmonary Arterial Hypertension.
Read
story.
|
|
